1. Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia

   • Anna Reyes-Travé
   • Laura Guarga-Solé
   • Joaquín Delgadillo-Duarte

   Practical Application Open access 10 June 2021 Pages: 973 - 982

   

2. Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework

   • Luca M. M. Janssen
   • Ruben M. W. A. Drost
   • Silvia M. A. A. Evers

   Scoping Review Open access 25 June 2021 Pages: 983 - 993

   

3. Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review

   • Joseph Khoa Ho
   • Kennedy Borle
   • Larry D. Lynd

   Systematic Review 22 June 2021 Pages: 995 - 1019

   

4. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel

   • Karen M. Facey
   • Jaime Espin
   • Sheela Upadhyaya

   Original Research Article Open access 07 July 2021 Pages: 1021 - 1044

5. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective

   • Daniel Stellato
   • Marroon E. Thabane
   • Thomas E. Delea

   Original Research Article 09 June 2021 Pages: 1045 - 1058

   

6. A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine

   • Erin Kirwin
   • Ellen Rafferty
   • Christopher McCabe

   Original Research Article Open access 17 June 2021 Pages: 1059 - 1073

   

7. Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)

   • Michael J. Zoratti
   • Kelvin K. W. Chan
   • the Health Utility Book (HUB) Working Group

   Original Research Article 21 June 2021 Pages: 1075 - 1084

   

8. Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment

   • Aureliano Paolo Finch
   • Eva Gamper
   • the EORTC Quality of Life Group

   Original Research Article Open access 03 July 2021 Pages: 1085 - 1098

   

9. Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

   • Becky Pennington
   • Abualbishr Alshreef
   • John Brazier

   Correction Open access 19 June 2021 Pages: 1099 - 1099